Calreticulin (CRT) binds to the MYCN 5′ proximal promoter, which may overlap with the binding site of the transcription factor E2F1 and is an inhibitor of MYCN. CRT-mediated MYCN inhibition leads to increased differentiation of MNA-NB. Here, E2F1 is linked to neuroblastoma.